Only the anti-CD40 11B6-CD40L-Cyclin D1 group showed reduction in tumor growth (Figure 11B), indicating the low impact of non-targeted antigen, or antigen targeted to CD40 without strong CD40 activation potential, versus the significantly improved ability of the anti-CD40-CD40L vehicle to partially control tumor growth. This evidence concerns the gene CD40LG and neoplasm.